SBFM's Business Model
Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound. It also offers Essential 9, a nutritional supplement tablet; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements. The company has a license agreement with the University of Georgia to advance the development of its anti-coronavirus lead compound, SBFM-PL4. Sunshine Biopharma, Inc. is headquartered in Pointe-Claire, Canada.
| Sector & Industry | Healthcare / Drug Manufacturers - Specialty & Generic |
| Website | https://www.sunshinebiopharma.com |
| CEO (Chief Executive Officer) | Steve N. Slilaty |
| Number of Employees | |
| IPO date | February 15, 2022 |
SBFM Latest News
|
|
|
|
|
|
|
|
|
|
| Contact | |
|---|---|
| Country | CA |
| Address | 6500 Trans-Canada Highway |
| City | Pointe-Claire |
| State | QC |
| Phone | 514 426 6161 |
| Zip Code | H9R 0A5 |
| Other Identifiers | |
| CIK | 0001402328 |
| ISIN | US8677817004 |
| CUSIP | 867781304 |
| Open | 1.22 |
| Previous Close | 1.15 |
| Volume | 4.43 Thou. |
| Average Volume | 59.52 Thou. |
| Day’s Range | 1.1623 – 1.22 |
| 52 Week Range | 1.15-3.9 |
| MA (50) | 1.32188 |
| MA (200) | 1.47802 |
| Market Cap | 5.72 Mil. |
| Shares Out. | 4.91 Mil. |
| Earnings Date | Feb 25, 2026 |
| Beta | |
| Last Dividend | |
| EPS | |
| PE | |
Industry Competitors for SBFM
|
Company
|
PE Ratio | Market Cap |
|---|---|---|
|
|
||
|
|
||
|
|
||
|
|
||
|
|
||
|
|
||
|
|
||
|
|
||
|
|
||
|
|